Additional file 1: of Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1

M. Peterschmitt; Selena Freisens; Lisa Underhill; Meredith Foster; Grace Lewis; Sebastiaan Gaemers

doi:10.6084/m9.figshare.8244914.v1

by M. Peterschmitt, Selena Freisens, Lisa Underhill, Meredith Foster, Grace Lewis, Sebastiaan Gaemers

Published by Figshare.

2019

Abstract

Table S1. Adverse events causing study discontinuation. Table S2. Cardiac adverse events reported by at least 2 patients in the pooled adverse events analysis (0.5% or more of total trials population). Table S3. Serious cardiac events. (PDF 127 kb)
In text/plain format

Archived Files and Locations

application/pdf 130.5 kB
file_4lr55576ujcpbbz6emk6dcrcwe s3-eu-west-1.amazonaws.com (web)
web.archive.org (webarchive)

Read Archived PDF

Preserved and Accessible

Type stub
Stage

published

Date 2019-06-08

DOI 10.6084/m9.figshare.8244914.v1

Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)

Cite This

BibTeX
CSL-JSON
MLA
Harvard

Lookup Links

oaDOI/unpaywall (OA fulltext)
Datacite Metadata (via API)
Worldcat
wikidata.org
CORE.ac.uk
Semantic Scholar
Google Scholar

Catalog Record
Revision: 86d35ba4-e64f-4cfb-8bfc-74a327fd9c2d
API URL: JSON

Edit Metadata View History

Additional file 1: of Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1 release_s2jepd4hofc4tetia6hdp5b3gm

Abstract

Archived Files and Locations

Additional file 1: of Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1 `release_s2jepd4hofc4tetia6hdp5b3gm`